ACE2 and autoimmune uveitis: In experimental models of mouse autoimmune uveitis or of endotoxin-induced uveitis, the delivery of different formulations of ACE2 and/or Ang (1–7), as well as the administration of an ACE2 activator reduced retinal inflammation [42,43,44] and prevented histologic damage and functional deficits [43].